格隆汇3月12日丨金斯瑞生物科技(01548.HK)发布公告,截至2024年12月31日止年度,集团收益持续增长。报告期内集团持续经营业务的收益约为5.945亿美元,较上期的约5.605亿美元增加6.1%。报告期内集团持续经营业务的毛利约为2.721亿美元,较上期保持稳定。报告期内集团的利润约为29亿美元,而上期集团的亏损约为3.551亿美元,其中,持续经营业务的亏损约为1.738亿美元,而上期的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.